Kompletní patologická odpověď po neoadjuvantní chemoterapii a profit z následné chirurgické léčby u pacienta s oligometastatickým karcinomem pankreatu

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F24%3A73628330" target="_blank" >RIV/61989592:15110/24:73628330 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15120/24:73628330

Výsledek na webu

<a href="https://www.perspinsurg.com/rvch/article/view/1050" target="_blank" >https://www.perspinsurg.com/rvch/article/view/1050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.48095/ccrvch2024454" target="_blank" >10.48095/ccrvch2024454</a>

Jazyk výsledku

čeština

Název v původním jazyce

Kompletní patologická odpověď po neoadjuvantní chemoterapii a profit z následné chirurgické léčby u pacienta s oligometastatickým karcinomem pankreatu

Popis výsledku v původním jazyce

INTRODUCTION: Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.  -Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trials defining strategy, efficacy and safety of this procedure. PATIENT CONCERNS: A 77-year-old man presented with a mass in the tail of the pancreas and solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomy with liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residual adenocarcinoma in liver metastasis. OUTCOMES: The patient is alive without recurrency more than two years from the diagnosis.

Název v anglickém jazyce

Complete pathological response after neoadjuvant chemotherapy and the benefit of subsequent surgery in oligometastatic pancreatic cancer patient

Popis výsledku anglicky

Introduction: Pancreatic cancer is one of the most aggressive tumors diagnosed in locally advanced or metastatic stage in more than half of the cases. The standard of care isa systemic chemotherapy but the prognosis of metastatic patients remains extremelypoor with a median overall survival less than one year. However, there is increasingevidence of surgery treatment benefit in a carefully selected oligometastatic cases.Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trialsdefining strategy, efficacy and safety of this procedure.Patient concerns: A 77-year-old man presented with a mass in the tail of the pancreaand solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomywith liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residualadenocarcinoma in liver metastasis.Outcomes: The patient is alive without recurrency more than two years from the diagnosis.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Rozhledy v chirurgii

ISSN

1805-4579

e-ISSN

0035-9351

Svazek periodika

103

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

454-457

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85212033427